頁 1 從 60 結果
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage of International Patent Application No. PCT/CN2011/079731, filed on Sep. 16, 2011, which claims the benefit of priority under 35 U.S.C. .sctn.119 from the following Chinese patent applications: Chinese Patent
FIELD OF THE INVENTION
This application discloses a device for body massage and in particular an ergonomic therapeutic massage device.
BACKGROUND OF TEE INVENTION
Massage is the physiologically and psychologically therapeutic manipulation of muscles, tendons, ligaments and cartilage, with the
This application includes as part of its disclosure a biological sequence listing which is being concurrently submitted through EFS-Web. Said biological sequence listing is contained in a file named "56256o1204.txt" which was created on Dec. 15, 2016, and has a size of 238,677 bytes, and is hereby
The sequence listing in the file named "67858o702005.txt" having a size of 238,525 bytes that was created Nov. 25, 2008 is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in
This application claims priority to U.S. Ser. No. 12/153,612 filed May 21, 2008, U.S. Ser. No. 12/153,611 filed May 21, 2008, U.S. Ser. No. 12/124,723 filed May 21, 2008, provisional patent application No. 60/924,550, filed May 21, 2007, and provisional patent application No. 60/924,551, filed May
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in the above-referenced patent applications relating to novel anti-IL-6 antibodies and novel therapies and therapeutic protocols using anti-IL-6 antibodies, preferably those
BACKGROUND OF THE INVENTION
Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in the above-referenced patent applications relating to novel anti-IL-6 antibodies and novel therapies and therapeutic protocols using anti-IL-6 antibodies, preferably those
BACKGROUND OF THE INVENTION
Field of the Invention
This invention is an extension of Applicants' prior invention disclosed in the above-referenced patent applications relating to novel anti-IL-6 antibodies and novel therapies and therapeutic protocols using anti-IL-6 antibodies, preferably those
TECHNICAL FIELD
The present invention relates to the field of therapeutic uses for erythropoietin, and more particularly, to treating subjects with a recombinant erythropoietin prepared from an Apa I human genomic DNA fragment, including recombinant erythropoietin expressed in transformed baby
FIELD OF THE INVENTION
The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, Fabry's disease, fibromyalgia, Parkinson's disease, or traumatic brain injury using cyclobenzaprine. The present invention
FIELD OF THE INVENTION
The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, Fabry's disease, fibromyalgia, Parkinson's disease, or traumatic brain injury using cyclobenzaprine. The present invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods of treating individuals suffering from a variety of conditions wherein inhibiting reuptake of norepinephrine provides a benefit. In particular, the present invention relates to methods of treatment
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods of treating individuals suffering from a variety of conditions wherein inhibiting reuptake of norepinephrine provides a benefit. In particular, the present invention relates to methods of treatment
TECHNICAL FIELD
The present invention relates to the field of ergonomic and safety anti-fatigue matting.
BACKGROUND OF THE INVENTION
Work-related musculoskeletal disorders (MSD) result when there is a mismatch between the physical capacity of workers and the demands of the job. Musculoskeletal
The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome.
BACKGROUND
Chronic fatigue syndrome (CFS) is a complex disorder, defined by the international Fukuda criteria (Fukuda K, et al., The chronic fatigue